Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies

 
• By Sten Stovall
  
Targets
Immatics To Use Series E Funds To Progress Multi Targeted Therapies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business